Results 111 to 120 of about 9,895 (222)

Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment

Clinical and Translational Science
In vitro data are routinely used to support both static and physiologically based pharmacokinetic (PBPK) model‐based drug–drug interaction (DDI) predictions.
David Rodrigues, Christopher R. Gibson, Nina Isoherranen   +2 more
doaj   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation

CPT: Pharmacometrics & Systems Pharmacology
Physiologically Based Pharmacokinetic (PBPK) modeling is a powerful tool in drug development that integrates drug‐specific information with physiological parameters to predict drug concentrations.
Donato Teutonico, David Marchionni, Marc Lavielle, Laurent Nguyen   +3 more
doaj   +1 more source

Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial [PDF]

Physiologically based pharmacokinetic (PBPK) modelling for biologics, such as monoclonal antibodies and therapeutic proteins, involves capturing complex processes, including target-mediated drug disposition (TMDD), FcRn-mediated recycling, and tissue ...
Qier Wu, Felix Stader, Abdallah Derbalah, Tariq Abdulla, Masoud Jamei, Armin Sepp, Iain Gardner, Mailys De Sousa Mendes   +7 more
core   +1 more source

Schematic illustration of the presented Bayesian population PBPK approach. [PDF]

, 2015
(A) A Bayesian framework is combined with a detailed mechanistic PBPK model, where a Markov chain Monte Carlo (MCMC) approach is considered to identify the high dimensional parameter distribution.
Lars Kuepfer (31319), Linus Goerlitz (802842), Andreas Schuppert (104374), Markus Krauss (124200), Kai Tappe (802841)   +4 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling

Drug Design, Development and Therapy
Fengjiao Bu,1,2,* Yong-Soon Cho,3,4,* Qingfeng He,1 Xiaowen Wang,1 Saurav Howlader,3,4 Dong-Hyun Kim,3,4 Mingshe Zhu,5 Jae Gook Shin,3,4 Xiaoqiang Xiang1,6 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan ...
Bu F, Cho YS, He Q, Wang X, Howlader S, Kim DH, Zhu M, Shin JG, Xiang X   +8 more
doaj  

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna [PDF]

, 2018
The goal of the current work was to implement and verify previously published rat and human PBPK modelling codes for TCDD into Berkeley Madonna. The US‐EPA has used these PBPK models in the reassessment of TCDD.
Punt, Ans, Ossendorp, Bernadette
core   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source